European equities traded in the US as American depositary receipts were tracking sharply lower late Tuesday morning, declining 1.71% to 1,313.74 on the S&P Europe Select ADR Index. From continental ...
Nucana (NCNA) has released an update. NuCana’s recent Phase 1b/2 study results reveal promising efficacy of its new drug NUC-3373 in combination with pembrolizumab and docetaxel for patients with ...
NuCana (NCNA) announced that initial data from the ongoing Phase 1b/2 modular study investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors ...
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival ...